1. Girolimetti G, Perrone AM, Santini D, et al. BRCA-associated ovarian cancer: from molecular genetics to risk management. Biomed Res Int. 2014;2014:787143.
2. National Cancer Institute. BRCA1 and BRCA2: cancer risk and genetic testing. 2014. http://www.cancer.gov/cancertopics/factsheet/Risk/BRCA . Accessed 24 Nov 2014.
3. Javle M, Curtin NJ. The role of PARP in DNA repair and its therapeutic exploitation. Br J Cancer. 2011;105(8):1114–22.
4. AstraZeneca AB. Lynparza 50 mg hard capsules: EU summary of product characteristics. 2014. http://www.ema.europa.eu/ema . Accessed 12 Jan 2015.
5. AstraZeneca Pharmaceuticals LP. Lynparza™ (olaparib) capsules, for oral use: US prescribing information. 2014. http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm . Accessed 5 Jan 2015.